Peritoneal Malignant Mesothelioma Metastasizing to Lymph Node in Young Male-a Case Report

Indian Journal of Surgical Oncology 2024 March [Link] Amanpreet Singh, Cherry Bansal, Disha Singla, Sarika More, Shivani Chabhra, Shazia Bashir Abstract Peritoneal malignant mesothelioma is an uncommon neoplasm with a poor prognosis. We hereby report a case of a 20-year-old male, first diagnosed on biopsy with axillary lymph node metastasis. He presented with abdominal pain…

Read More

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

European Journal of Cancer 2024 March 1 [Link] Vilde Drageset Haakensen, Åsa Kristina Öjlert, Solfrid Thunold, Saima Farooqi, Anna K Nowak, Wee L Chin, Oscar Grundberg, Weronika Maria Szejniuk, Susana Cedres, Jens Benn Sørensen, Tonje Sofie Dalen, Marius Lund-Iversen, Maria Bjaanæs, Åslaug Helland Abstract Purpose: The NIPU-trial investigates the effect of adding the telomerase vaccine…

Read More

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma

Cancer Genomics & Proteomics 2024 March-April [Link] Daiki Shimizu, Miku Ishibashi, Tadaaki Yamada, Yuki Toda, Shigekuni Hosogi, Eishi Ashihara Abstract Background/aim: The prognosis of patients with malignant pleural mesothelioma (MPM) remains poor due to lack of effective therapeutic targets. DNA damage caused by long-time exposure to asbestos fibers has been associated with the development of…

Read More

CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma

International Journal of Molecular Sciences 2024 February 14 [Link] Shoji Okado, Taketo Kato, Yuki Hanamatsu, Ryo Emoto, Yoshito Imamura, Hiroki Watanabe, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tamotsu Takeuchi, Shigeyuki Matsui, Toyofumi Fengshi Chen-Yoshikawa Abstract Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this…

Read More

Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes

Current Oncology 2024 February 14 [Link] Andrew Baird, Abdullah Nasser, Peter Tanuseputro, Colleen Webber, Paul Wheatley-Price, Camille Munro Abstract Malignant pleural mesothelioma is a rare, aggressive, and incurable cancer with a poor prognosis and high symptom burden. For these patients, little is known about the impact of palliative care consultation on outcomes such as mortality,…

Read More

Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk

Annals of Surgical Oncology 2024 February 19 [Link] Varun V Bansal, Owen Mitchell, Celyn Bregio, Hunter D D Witmer, Ankit Dhiman, Frederick A Godley 4th, Cecilia Ong, Yaniv Berger, Biren Reddy, Jane E Churpek, Michael W Drazer, Oliver S Eng, Hedy L Kindler, Kiran K Turaga Abstract Introduction: Venous thromboembolism (VTE) is a common complication…

Read More

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial

JAMA Oncology 2024 February 15 [Link] Peter W Szlosarek, Benjamin C Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L Ceresoli, Aaron S Mansfield, Anne Tsao, Kenneth J O’Byrne, Anna K Nowak, Jeremy Steele, Michael Sheaff, Chiung-Fang Shiu, Chih-Ling…

Read More

Is extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?

Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…

Read More

BAP1, Wilms’ tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma

Journal of Cancer Research and Clinical Oncology 2024 January 27 [Link] Tuna Han Yuce, Guntulu Ak, Selma Metintas, Emine Dundar, Oluf Dimitri Roe, Vasiliki Panou, Muzaffer Metintas Abstract Purpose: There are currently no methods to predict response to chemotherapy in pleural mesothelioma (PM). The aim of this study is to investigate the predictive and prognostic…

Read More